Tarsus Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Tarsus Pharmaceuticals's earnings have been declining at an average annual rate of -61.6%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 23.5% per year.
Key information
-61.6%
Earnings growth rate
-12.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 23.5% |
| Return on equity | -69.0% |
| Net Margin | -778.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids
Sep 07Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
May 13A Look At The Fair Value Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Dec 07Revenue & Expenses BreakdownBeta
How Tarsus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 17 | -136 | 109 | 0 |
| 30 Sep 23 | 14 | -108 | 80 | 0 |
| 30 Jun 23 | 13 | -91 | 62 | 0 |
| 31 Mar 23 | 28 | -65 | 52 | 0 |
| 31 Dec 22 | 26 | -62 | 45 | 0 |
| 30 Sep 22 | 16 | -63 | 37 | 0 |
| 30 Jun 22 | 17 | -56 | 32 | 0 |
| 31 Mar 22 | 24 | -44 | 28 | 0 |
| 31 Dec 21 | 57 | -14 | 25 | 0 |
| 30 Sep 21 | 57 | -10 | 23 | 0 |
| 30 Jun 21 | 55 | -5 | 18 | 0 |
| 31 Mar 21 | 33 | -15 | 13 | -2 |
| 31 Dec 20 | 0 | -27 | 8 | 0 |
| 30 Sep 20 | 0 | -17 | 5 | 1 |
| 30 Jun 20 | 0 | -7 | 3 | 1 |
| 31 Mar 20 | 0 | -5 | 1 | 4 |
| 31 Dec 19 | 0 | -5 | 1 | 3 |
Quality Earnings: TARS is currently unprofitable.
Growing Profit Margin: TARS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TARS is unprofitable, and losses have increased over the past 5 years at a rate of 61.6% per year.
Accelerating Growth: Unable to compare TARS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TARS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-14.6%).
Return on Equity
High ROE: TARS has a negative Return on Equity (-68.99%), as it is currently unprofitable.